Trial Profile
A randomized, placebo-controlled trial of CAP-1002 for patients with moderate and severe COVID-19 disease
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 04 May 2020
Price :
$35
*
At a glance
- Drugs CAP-1002 (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 04 May 2020 New trial record
- 29 Apr 2020 According to a Capricor Therapeutics media release, this trial will be funded by non-equity capital.